Abstract
Overall, data suggest an increase in transgendered-related diagnoses, possibly reflecting accelerated openness and awareness in both the lay and medical communities about health concerns specific to transsexual individuals. It is hypothesized that a combination of prenatal sex hormonal milieu, genetics, and differences in sexually dimorphic brain structures may be important in the pathophysiology of transsexualism. The diagnosis of transsexualism is generally made by a mental health professional and it is key to identify potential psychiatric comorbidities prior to consideration of hormonal or surgical therapy. Both the Endocrine Society guidelines and WPATH Standards of Care provide excellent clinical guidance on the management of transsexual adults. Gender-affirming hormone therapy for transsexual women typically includes an antiandrogen agent and estrogen and for transsexual men includes testosterone. If the decision to go forward with gender-affirming surgery is made, it is recommended that individuals live as the desired gender for at least 1 year prior. Prior to going forward with hormone or surgical therapy, it is important to address fertility preservation. Lifelong surveillance is recommended to address the unique primary care concerns of this population. There is a clear need for well-conducted research in characterizing health disparities, comorbid disease, and the effects of gender-affirming hormonal and surgical interventions on morbidity, mortality, and quality of life.
| Original language | English (US) |
|---|---|
| Title of host publication | Principles of Gender-Specific Medicine |
| Subtitle of host publication | Gender in the Genomic Era: Third Edition |
| Publisher | Elsevier |
| Pages | 91-105 |
| Number of pages | 15 |
| ISBN (Print) | 9780128035061 |
| DOIs | |
| State | Published - May 15 2017 |
Fingerprint
Keywords
- Gender affirming hormone therapy
- Gender affirming surgery
- Transgender
- Transsexual
ASJC Scopus subject areas
- Medicine(all)
Cite this
The Transsexual Adult. / Yalamanchi, Swaytha; Fesseha, Betiel; Dobs, Adrian S.
Principles of Gender-Specific Medicine: Gender in the Genomic Era: Third Edition. Elsevier, 2017. p. 91-105.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - The Transsexual Adult
AU - Yalamanchi, Swaytha
AU - Fesseha, Betiel
AU - Dobs, Adrian S
PY - 2017/5/15
Y1 - 2017/5/15
N2 - Overall, data suggest an increase in transgendered-related diagnoses, possibly reflecting accelerated openness and awareness in both the lay and medical communities about health concerns specific to transsexual individuals. It is hypothesized that a combination of prenatal sex hormonal milieu, genetics, and differences in sexually dimorphic brain structures may be important in the pathophysiology of transsexualism. The diagnosis of transsexualism is generally made by a mental health professional and it is key to identify potential psychiatric comorbidities prior to consideration of hormonal or surgical therapy. Both the Endocrine Society guidelines and WPATH Standards of Care provide excellent clinical guidance on the management of transsexual adults. Gender-affirming hormone therapy for transsexual women typically includes an antiandrogen agent and estrogen and for transsexual men includes testosterone. If the decision to go forward with gender-affirming surgery is made, it is recommended that individuals live as the desired gender for at least 1 year prior. Prior to going forward with hormone or surgical therapy, it is important to address fertility preservation. Lifelong surveillance is recommended to address the unique primary care concerns of this population. There is a clear need for well-conducted research in characterizing health disparities, comorbid disease, and the effects of gender-affirming hormonal and surgical interventions on morbidity, mortality, and quality of life.
AB - Overall, data suggest an increase in transgendered-related diagnoses, possibly reflecting accelerated openness and awareness in both the lay and medical communities about health concerns specific to transsexual individuals. It is hypothesized that a combination of prenatal sex hormonal milieu, genetics, and differences in sexually dimorphic brain structures may be important in the pathophysiology of transsexualism. The diagnosis of transsexualism is generally made by a mental health professional and it is key to identify potential psychiatric comorbidities prior to consideration of hormonal or surgical therapy. Both the Endocrine Society guidelines and WPATH Standards of Care provide excellent clinical guidance on the management of transsexual adults. Gender-affirming hormone therapy for transsexual women typically includes an antiandrogen agent and estrogen and for transsexual men includes testosterone. If the decision to go forward with gender-affirming surgery is made, it is recommended that individuals live as the desired gender for at least 1 year prior. Prior to going forward with hormone or surgical therapy, it is important to address fertility preservation. Lifelong surveillance is recommended to address the unique primary care concerns of this population. There is a clear need for well-conducted research in characterizing health disparities, comorbid disease, and the effects of gender-affirming hormonal and surgical interventions on morbidity, mortality, and quality of life.
KW - Gender affirming hormone therapy
KW - Gender affirming surgery
KW - Transgender
KW - Transsexual
UR - http://www.scopus.com/inward/record.url?scp=85032633815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032633815&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-803506-1.00015-2
DO - 10.1016/B978-0-12-803506-1.00015-2
M3 - Chapter
AN - SCOPUS:85032633815
SN - 9780128035061
SP - 91
EP - 105
BT - Principles of Gender-Specific Medicine
PB - Elsevier
ER -